Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

L. Topalian, Suzanne; Sznol, Mario; F. McDermott, David; M. Kluger, Harriet; D. Carvajal, Richard; H. Sharfman, William; R. Brahmer, Julie; P. Lawrence, Donald; B. Atkins, Michael; D. Powderly, John; D. Leming, Philip; J. Lipson, Evan; Puzanov, Igor; C. Smith, David; M. Taube, Janis; M. Wigginton, Jon; Kollia, Georgia; Gupta, Ashok; M. Pardoll, Drew; A. Sosman, Jeffrey; Stephen Hodi, F.

doi:10.1200/jco.2013.53.0105

Public

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

Published in Journal of Clinical Oncology • Mar 4, 2014

Authors:

Suzanne L. Topalian

Mario Sznol

David F. McDermott

Abstract

PURPOSE: Programmed cell death 1 (PD-1) is an inhibitory receptor expressed by activated T cells that downmodulates effector functions and limits the generation of immune memory. PD-1 blockade can mediate tumor regression in a substantial proportion of patients with melanoma, but it is not known whe...

Subject

Medicine

Nivolumab

Discontinuation

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!